NCT00392665View on ClinicalTrials.gov

Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck

PHASE2TerminatedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

August 31, 2012

Study Completion Date

December 31, 2013

Conditions
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions
DRUG

Bevacizumab

Given intravenously on day one of each 3 week cycle

DRUG

erlotinib

Given orally once a day

DRUG

Sulindac

Given orally twice a day

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Emory University

OTHER

collaborator

University of North Carolina, Chapel Hill

OTHER

collaborator

Genentech, Inc.

INDUSTRY

collaborator

OSI Pharmaceuticals

INDUSTRY

lead

Massachusetts General Hospital

OTHER